公开(公告)号：US20050138690A1

公开(公告)日：2005-06-23

申请号：US11042574

申请日：2005-01-24

申请人： Mohan Singh ,  Prem Bhalla ,  Hui-Ling Xu ,  Ines Swoboda ,  Manjit Singh

发明人： Mohan Singh ,  Prem Bhalla ,  Hui-Ling Xu ,  Ines Swoboda ,  Manjit Singh

IPC分类号： C12N15/09 ,  A01H5/00 ,  C07K14/415 ,  C12N5/10 ,  C12N15/29 ,  C12N15/82 ,  A01H1/00 ,  C12N5/04 ,  C12Q1/68

CPC分类号： C07K14/415 ,  C12N15/8231 ,  C12N15/8289

摘要： The present invention relates generally to a novel nucleic acid molecule. More particularly, the present invention relates to a male germ line cell specific genetic sequence in plants. Male germ line cells include generative cells and sperm cells. Even more particularly, the present invention provides a male germ line specific gene or functional equivalent thereof. This invention is also directed to the promoter of said gene or its functional derivatives and their use in generating a range of mutant plants including male sterile plants and transposon tagged plants. Preferred nucleic acid molecules of the present invention include the LGC1 gene as well as homologs and derivatives thereof.

摘要翻译： 本发明一般涉及新的核酸分子。 更具体地说，本发明涉及植物中的雄性种系细胞特异性遗传序列。 雄性生殖细胞包括生殖细胞和精子细胞。 更具体地，本发明提供了雄性种系特异性基因或其功能等同物。 本发明还涉及所述基因的启动子或其功能衍生物及其在产生一系列突变植物（包括雄性不育植物和转座子标记植物）中的用途。 本发明优选的核酸分子包括LGC1基因及其同源物及其衍生物。

公开(公告)号：US20050074464A1

公开(公告)日：2005-04-07

申请号：US10490305

申请日：2002-09-13

申请人： Nicole Deweerd ,  Mohan Singh ,  Prem Bhalla ,  Ines Swoboda

发明人： Nicole Deweerd ,  Mohan Singh ,  Prem Bhalla ,  Ines Swoboda

IPC分类号： C12N15/09 ,  A61K39/36 ,  A61P37/08 ,  C07K14/415 ,  C07K16/16 ,  C12N15/13 ,  A61K39/00

CPC分类号： C07K16/16 ,  A61K39/36 ,  A61K2039/57 ,  A61K2039/577 ,  C07K14/415

摘要： The present invention relates generally to reagents useful in the immunotherapeutic or immunoprophylactic treatment of allergic diseases. More particularly, the present invention provides modified allergens exhibiting reduced IgE interactivity including reduced IgE production-stimulatory activity, while retaining T-cell antigenicity, which are useful in the immunomodulation of type I allergic disease conditions. The present invention further contemplates a method of immunomodulation of allergic diseases such as type I allergic disease conditions by the administration of modified allergens exhibiting reduced IgE interactivity while retaining T-cell antigenicity.

摘要翻译： 本发明一般涉及可用于过敏性疾病的免疫治疗或免疫预防治疗的试剂。 更具体地，本发明提供了改善的变应原，其表现出减少的IgE相互作用，包括降低的IgE产生刺激活性，同时保留了可用于I型过敏性疾病病症的免疫调节的T细胞抗原性。 本发明进一步考虑了通过施用具有降低的IgE相互作用的修饰的变应原同时保留T细胞抗原性的过敏性疾病例如I型过敏性疾病病症的免疫调节的方法。